Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

What does recovery really look like after aggressive peritoneal cancer surgery?

NCT ID NCT03503071

Knowledge-focused Sponsor: Kyungpook National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study follows people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis) or with pseudomyxoma peritonei, a rare tumor of the abdominal cavity. Participants undergo cytoreductive surgery to remove all visible tumors, followed by intraperitoneal chemotherapy delivered directly into the abdomen. The goal is to measure how pain and overall quality of life change during the recovery period, using standard questionnaires. The findings could help set realistic expectations and improve support for patients facing this demanding treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cytoreductive surgery combined with intraperitoneal chemotherapy (either early postoperative or hyperthermic)
What this could lead to
If successful, this could help doctors better prepare patients for the recovery journey after this intensive treatment, improving supportive care and quality of life.
What could go wrong
This is an observational study, so it won't test a new treatment. The results may not apply to all patients, and recovery experiences can vary widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Oct 2018

An estimate. Start dates often move.

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients eligible for cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer peritoneal metastasis or pseudomyxoma peritonei

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Colorectal cancer peritoneal metastasis * Pseudomyxoma peritonei * ECOG (Eastern Cooperative Oncology Group) performance status 0-3 * Normal bone marrow, kidney, and liver function * Patient must sign and date the informed consent Exclusion Criteria: * Palliative surgery * Palliative intraperitoneal chemotherapy * Psychotic disorder * Drug abuser

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer metastatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer peritoneal carcinomatosis pseudomyxoma peritonei

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer metastatic

Contacts and locations

Locations

  • Kyungpook National University Chilgok Hospital

    Daegu, 41404, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.